Accession Number:

AD1026506

Title:

Role of Hypomethylating Agents in the Treatment of Bone Marrow Failure

Descriptive Note:

Technical Report,30 Sep 2015,29 Sep 2016

Corporate Author:

The Brigham and Womens Hospital, Inc Boston United States

Personal Author(s):

• Ebert,Benjamin L.

Report Date:

2016-10-01

Pagination or Media Count:

24.0

Abstract:

The central goal of this project is to identify mutations that alter sensitivity to hypomethylating agents. Initial studies indicated that TET2 mutant MDS cells are sensitive to these drugs. In the past year, we have used functional studies, as proposed in Aim 2, to find that cells with cohesin gene mutations are sensitized to hypomethylating agents. We used CRISPRCas9genome engineering of primary human hematopoietic stem and progenitor cells HSPCs, the cells of origin for myeloid malignancies to study and validate this finding. In this model, we first validated that TET2 mutations increased the sensitivity of cells to azacitidine, and ASXL1 mutations decreased sensitivity to azacitidine, recapitulating the human genetic data described in Aim 1A. In addition, we found that cohesin-mutated hematopoietic cells were sensitive to azacitidine treatment. We have validated this finding in cell lines with engineered cohesin gene mutations. The establishment of insulated neighborhoods, keyfunctional elements of chromatin structure, are defined by CTCF-cohesin complexes. Binding of CTCF is highly methylation sensitive. We are therefore examining whether hypomethylating agents alter CTCF binding and disrupt the aberrant insulated neighborhoods found in cohesin-mutated MDS.

Descriptors:

• bone marrow
• leukemia
• mutations
• gene expression
• CELL BIOLOGY

Subject Categories:

• Anatomy and Physiology
• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE